CMS Open Payments · Program Year 2024
Ardelyx, Inc.
Ardelyx, Inc. reported $2,632,099.04 across General Payments, Research, and Ownership to 42,247 physicians and teaching hospitals across 42,443 transactions.
- $2.6M Top quartile payer
- All-tracks total
- 42,443 Top 10% volume
- Transactions
- 42,247 Top 10% reach
- Recipients
- +$417.1K
- General Payments vs PY2023
Ardelyx, Inc. reported $2,632,099.04 across all CMS Open Payments tracks (General + Research + Ownership) to 42,247 physicians and teaching hospitals in Program Year 2024 - ranking #394 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,814,059.60, averaging $62.30 per recipient.
How Ardelyx, Inc.'s $2.6M all-tracks total breaks down
Ardelyx, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
C
78/100
Total payments
F
34/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
C
77/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer ardelyx-inc Ardelyx, Inc.
$2.6M · #394/1,925 · 0.0% industry · PY2024
- TOT $2.6M
- RANK #394
- SHARE 0.0%
- TXN 42,443
- RCP 42,247
- CAT 6
- GEN $1.8M
- ΔGEN +$417.1K
- TOP1 6.9%
- PY 2024
Volume peers
Nearest volume peer: Cerus Corporation ($2.6M)
Ardelyx, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Ardelyx, Inc.'s CMS-reported General Payments increased by $417.1K (+29.9%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ARDELYX, INC.PY2023: ARDELYX, INC.PY2024: Ardelyx, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,397,001.72
- PY2024
- $1,814,059.60
What the Data Shows for Ardelyx, Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Ardelyx, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
"Food and Beverage" leads the 6-category general-payment breakdown below at $1.0M (56.6% of General Payments, 41,754 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 6 types of general payments, Ardelyx, Inc.'s largest category was "Food and Beverage" at $1.0M - 56.6% of General Payments.
Ardelyx, Inc. reports 6 general-payment categories - the top three are Food and Beverage (56.6%), Consulting Fee (32.7%), and Compensation for Services Other Than Consulting (5.6%). The remaining 3 categories make up 5.1% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Ardelyx, Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $1.0M | 41,754 | 56.6% |
| Consulting Fee | $592.4K | 313 | 32.7% |
| Compensation for Services Other Than Consulting | $102.1K | 32 | 5.6% |
| Travel and Lodging | $65.4K | 130 | 3.6% |
| Education | $23.0K | 8 | 1.3% |
| Grant | $4.5K | 10 | 0.2% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $322,973.30 (17.8%) of $1,814,059.60 in this company's General Payments records across 16,797 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Ardelyx, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Massachusetts General Hospital
$124,320.00 across 12 reported transactions
- 2
Cedars-Sinai Medical Center
$57,000.00 across 1 reported transactions
- 3
Kavita Kongara
$51,805.94 across 46 reported transactions
- 4
Darren Brenner
$45,191.30 across 39 reported transactions
- 5
Satish Rao
$44,656.06 across 36 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Ardelyx, Inc. ranks #394 of 1,925 by total payments (top 20% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,691 of 1,838 by HHI (bottom 8% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Vifor Pharma, Inc. : $368.6K total payments, HHI 106
- Grifols USA, LLC : $2.0M total payments, HHI 105
- Neurelis, Inc. : $1.9M total payments, HHI 104
- ACADIA Pharmaceuticals Inc : $2.6M total payments, HHI 102
- Biotronik Inc. : $2.4M total payments, HHI 102
- CSL Plasma Inc. : $17.9M total payments, HHI 100
- Ardelyx, Inc. (this company) : $1.8M total payments, HHI 99
- Synthes GmbH : $2.5M total payments, HHI 99
- ANI Pharmaceuticals, Inc. : $1.1M total payments, HHI 98
- Arcutis Biotherapeutics, Inc. : $5.0M total payments, HHI 97
- CVRx, Inc. : $1.5M total payments, HHI 97
- Peerless Surgical Inc. : $139.0K total payments, HHI 96
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Ardelyx, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Ardelyx, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Ardelyx, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Tosoh Bioscience, Inc.
Global Blood Therapeutics, Inc.
Acella Pharmaceuticals, LLC
Vertical Orthopaedics, Inc.
Calyxo, Inc.
Put this to use
Ardelyx, Inc. ranks #394 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See where Ardelyx, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Ardelyx, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.